RegulatoryCompany release
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
The US regulator has added RMAT status to iSCIB1+ for advanced melanoma, which already holds Fast Track, as Scancell prepares to dose the first Phase 3 patient in December.
Scancell Holdings said on 19 November 2026 that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to iSCIB1+ for advanced melanoma. The DNA vaccine, which now has the agreed WHO international nonproprietary name inzitagene plasmivec, already held Fast Track status.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release: Scancell Holdings plc ↗
Article written by VigiEye from the official source (Scancell Holdings plc). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 190/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends veterinary, phytosanitary and technical regulation annexes in Decision No 194/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 191/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026